In the semaglutide-only group, around 35% of people’s lost weight by week 26 was lean body mass. But in the two semaglutide plus trevogrumab groups, this percentage was 17%, while people in the ...

In a Phase 2b trial, older patients taking Novo Nordisk’s Wegovy and Veru’s experimental drug, called enobosarm, lost on average 1.2% of lean mass after 16 weeks, compared with a 4.1% loss in ...

Scholar Rock is not alone in attempting to preserve lean mass during drug-induced weight loss. Earlier this month, Regeneron (REGN) said that a mid-stage trial demonstrated that approximately 35% ...

Scholar Rock said on Wednesday a combination of its experimental drug and Eli Lilly's weight-loss treatment Zepbound helped overweight patients preserve significantly more lean mass in a mid-stage ...

Regeneron said on Monday its experimental drug helped patients preserve up to 51% of lean mass and lose more fat when used in combination with Novo Nordisk's popular obesity drug Wegovy in a mid ...

In a Phase 2b trial, older patients taking Novo Nordisk’s Wegovy and Veru’s experimental drug, called enobosarm, lost on average 1.2% of lean mass after 16 weeks, compared with a 4.1% loss in ...